Australian clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced a fully underwritten $121 million equity raising comprising a pro-rata accelerated non-renounceable entitlement offer and placement to institutional investors. …
Clarity Pharmaceuticals launches $121 million fully underwritten equity raising
March 26, 2024 Australian Biotech
Latest Video
New Stories
-
The need to honour a strong history while ensuring the future is guided by the 'good guys'
November 17, 2025 - - Latest News -
BMS Australia team cycles across Japan, raising nearly $20,000 for Bowel Cancer Australia
November 17, 2025 - - Latest News -
Syntara secures positive European opinion for orphan designation of amsulostat in myelofibrosis
November 17, 2025 - - Australian Biotech -
Mesoblast appoints Chief Financial Officer as it evolves into fully integrated commercial organisation
November 17, 2025 - - Australian Biotech -
Argent BioPharma secures significant financing facility to support strategic expansion
November 17, 2025 - - Australian Biotech -
Race Oncology launches new clinical programs in AML and lung cancer
November 17, 2025 - - Australian Biotech -
Noxopharm begins daily dosing in second phase of HERACLES trial
November 17, 2025 - - Australian Biotech